SEngine Precision Medicine receives $10 million in Series A+ financing

SEngine Precision Medicine is an American cancer-targeted drug developer. It uses sonic pipetting technology and uses the new testing platform PARIS to develop personalized drugs for each cancer patient; including small molecule inhibitors, etc. Get personalized advice. SEngine Precision Medicine recently announced the completion of a $10 million Series A+ financing led by Washington Research Foundation, Alethea Fulcrum Fund, Vincere Capital Biotech LLC, Bangarang Group and other investors.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.